Increased expression of IL-27Rα and JAM2 on aPCs from patients with MM. (A) BMA samples from patients with MM who were participating in the UKMRA Myeloma XII (ACCoRD) trial or from patients being treated for elective nonunion fracture repair (as healthy controls) were assessed via flow cytometry for the expression of IL-27Rα and JAM2. PCs were identified based on CD38/CD138-positivity followed by the distinction of aPC (CD56^hi CD19^lo) and healthy PC (hPC; CD56^lo CD19^hi). Representative dot plots and histograms showing the expression of IL-27Rα and JAM2 compared with that of isotype control in aPCs from patients with MM and PCs from healthy controls. (B-C) Data from individual patient samples from healthy controls and patients with MM (healthy PC in cases with sufficient events, see text) and aPC are shown; (B) IL27-Rα; (C) JAM2. ∗∗P < .01; ∗∗∗P < .001 using Student t test.